Albendazole treatment of echinococcosis in humans: Effects on microsomal metabolism and drug tolerance

Publisher Website
Google Scholar
Abstract
We prospectively studied the effects of albendazole on microsomal reserve and on first-pass activation to albendazole sulfoxide in patients with hydatid disease. An aminopyrine breath test was performed in 12 patients while they were receiving albendazole treatment and while they were not. Excretion of 14CO2 in breath averaged 0.70% .cntdot. kg mmol-1 .+-. 0.20% .cntdot. kg .cntdot. mmol-1 without treatment and 0.54% .cntdot. kg .cntdot. mmol-1 .+-. 0.14 .cntdot. kg .cntdot. mmol-1 with treatment (p < 0.005). Plasma levels of albendazole sulfoxide were measured 4 hours after the morning dose during the first and second half of the 4-week treatment cycles. In nine of the 12 patients albendazole sulfoxide levels decreased during the second half of the cycle by an average of 0.84 .+-. 0.76 .mu.mol/L (p < 0.02). Transaminase levels increased in 10 of the 12 patients during long-term albendazole treatment, and major side effects, including hepatotoxicity, neutropenia, and alopecia, were observed in three patients. We conclude that albendazole partially inhibits microsomal enzyme function but induces its own metabolism. Hepatotoxicity and other possible severe side effects necessitate close therapeutic monitoring of patients who are given albendazole.